Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003869 · ClinicalTrials.gov registry record · Phase 3
Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 186
- Enrollment target
NCT00003869: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00003869 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 186 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003869, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 186 participants
- Enrollment target
Study Summary
Randomized phase III trial to determine the effectiveness of carboxyamidotriazole in treating patients who have stage III or stage IV non-small cell lung cancer. Chemotherapeutic agents are modestly effective for the treatment of advanced lung cancer, with rapid tumor relapse and growth even after initial response to therapy. It is not yet known whether carboxyamidotriazole is more effective than no further treatment after standard chemotherapy for non-small cell lung cancer.
Interventions
- OTHER laboratory biomarker analysis
- OTHER placebo
- PROCEDURE quality-of-life assessment
- DRUG carboxyamidotriazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 1999-04 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003869
The ClinicalTrials.gov registry entry for NCT00003869 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00003869 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003869 about?
NCT00003869 is a clinical study titled "Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer". Randomized phase III trial to determine the effectiveness of carboxyamidotriazole in treating patients who have stage III or stage IV non-small cell lung cancer. Chemotherapeutic agents are modestly effective for the treatment of advanced lung cancer, with rapid tumor relapse and growth even after i...
What is the current status of trial NCT00003869?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 186 participants. The study started on 1999-04. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00003869?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), quality-of-life assessment (PROCEDURE), carboxyamidotriazole (DRUG).
Who is sponsoring clinical trial NCT00003869?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.